Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies Inc. (NYSE: A) will announce its first-quarter fiscal year 2021 financial results following the market close on February 16, 2021. A live webcast of the investor conference call will take place at 1:30 p.m. Pacific time on the same day. Agilent generated $5.34 billion in revenue during fiscal year 2020 and employs approximately 16,400 individuals worldwide. The webcast will be accessible for 90 days on the company's website.
Agilent Technologies (NYSE: A) launched MassHunter Workstation Plus 11.0 and MassHunter BioConfirm, enhancing data integrity compliance with US FDA and EU EMEA standards. Key features include user management, tamper detection, and audit trails, with shipments starting in June 2021. Additionally, VWorks 14.0 Plus is introduced for the Bravo Automated Liquid Handling Platform, aiding compliance in automated sample prep. These updates solidify Agilent's position in the pharma and biopharmaceutical sectors, as highlighted by their top ranking in compliance surveys.
Agilent Technologies (NYSE: A) has appointed Allison Ballmer as the new senior vice president of Strategy and Corporate Development. Reporting to CEO Mike McMullen, Ballmer will lead merger-and-acquisition efforts and drive enterprise strategy to foster growth. With nearly 20 years in the biotech sector, including significant experience at Roche, she brings valuable expertise to Agilent's Build-and-Buy growth strategy. Agilent generated $5.34 billion in revenue in fiscal year 2020 and employs over 16,400 people globally.
Agilent Technologies (NYSE: A) has received clearance from Japan's Ministry of Health for its GenetiSure Dx Postnatal Assay, a diagnostic tool for identifying genetic disorders. This assay, validated with 900 samples, allows clinicians to detect copy-number alterations and copy-neutral loss of heterozygosity. The SureScan Dx Scanner, a Class I medical device, will analyze the assay. Expected to launch commercially in the first half of 2021, this advancement enhances diagnostic options in Japan, following its previous availability in Europe and the U.S.
Agilent Technologies (NYSE: A) announced two upcoming webcasts for investors. The first is at the Goldman Sachs Healthcare CEOs Unscripted Conference on January 5, 2021, featuring CEO Mike McMullen. The second is at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021. These presentations aim to provide insights into the company's performance and strategy. In fiscal 2020, Agilent reported revenue of $5.34 billion and employs 16,400 people globally. More information can be found on their Investor Relations webpage.
Agilent Technologies (NYSE: A) announced that its NanoDis System and new polychromator in the 5800 and 5900 ICP-OES instruments received Innovation Awards from The Analytical Scientist. The NanoDis System enhances nanoparticle dissolution testing and streamlines drug market introduction. The redesigned polychromator improves analytical performance, reducing footprint and Argon gas consumption, marking a step towards sustainability. Agilent aims to advance science through its innovative technologies, contributing to vital sectors including health and environmental safety.
Agilent Technologies Inc. (NYSE: A) released its 19th annual Corporate Social Responsibility (CSR) report, detailing its 2019 achievements and actions in response to the 2020 global pandemic. Key highlights include 17% reduction in CO2 emissions per square foot, 85% solid waste diversion from landfills, and $7.5 million in philanthropic investments. Recognized as Barron’s no. 1 Most Sustainable Company for 2019, Agilent emphasizes environmental, social, and governance (ESG) strategies aimed at enhancing the quality of life globally.
Summary not available.
Agilent Technologies Inc. (NYSE: A) announces the adoption of its clinical informatics platform, Alissa Interpret, by the North West Genomic Laboratory Hub (NW GLH) in England. This platform enhances genomic testing capabilities by standardizing variant analysis and reporting on next-generation sequencing (NGS) data. Designed for efficiency, it integrates various genomic data types, supporting the interpretation of both rare diseases and cancer genomics. Agilent aims to improve diagnostic accuracy and reduce analysis time, addressing the growing demand for genomic testing solutions.
Agilent Technologies Inc. (NYSE: A) has unveiled its new Agilent 7850 ICP-MS System, designed to enhance productivity in ICP-MS analysis workflows. This innovative instrument features smart tools aimed at minimizing common time traps that can waste time and increase costs, particularly benefiting less experienced users in small to medium contract labs. The 7850's advanced software streamlines instrument setup and workflow, helping labs achieve high-quality results efficiently. With a revenue of $5.34 billion in fiscal 2020, Agilent continues to lead in the life sciences and diagnostics sector.